Ovarian Cancer: A Review
The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Importance: Ovarian cancer is the eighth most common cause of cancer and cancer death in women worldwide. In 2022, ovarian cancer was diagnosed in approximately 324 398 individuals, and 206 839 died of ovarian cancer worldwide. In 2025, it is estimated that 20 890 US women will be diagnosed with ovarian cancer and 12 730 patients will die of ovarian cancer. Observations: Approximately 90% of ovarian cancers are epithelial malignancies, of which 70% to 80% are high-grade serous ovarian cancers. Less common epithelial subtypes include endometrioid, clear cell, low-grade serous, mucinous, and carcinosarcoma. The median age at diagnosis of ovarian cancer is 63 years. Risk factors include older age, family history of breast or ovarian cancer, endometriosis, and nulliparity. Hereditary factors are associated with 25% of cases, predominantly linked to BRCA1/2 gene variants. At diagnosis, approximately 95% of patients experience nonspecific symptoms, such as abdominal pain, bloating, and urinary urgency and frequency, and about 80% have advanced-stage disease (stage III-IV), including extrapelvic disease, ascites, and abdominal masses. Diagnostic and staging evaluation includes pelvic ultrasound; computed tomography of the chest, abdomen, and pelvis; and serum tumor markers such as carbohydrate antigen 125, carbohydrate antigen 19-9, and carcinoembryonic antigen. First-line treatment for early-stage ovarian cancer, defined as limited to the ovary or fallopian tube (stage I) or confined to the pelvis (stage II), is surgery (hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy), followed by adjuvant chemotherapy (carboplatin and paclitaxel). With treatment, early-stage ovarian cancer has a 5-year overall survival of 70% to 95%. Advanced-stage ovarian cancer may be treated with primary cytoreductive surgery (removal of all visible cancer in the abdominal cavity) and adjuvant chemotherapy (carboplatin and paclitaxel) or with neoadjuvant chemotherapy followed by cytoreductive surgery and adjuvant chemotherapy. Most patients with advanced-stage ovarian cancer receive maintenance therapy with bevacizumab (a monoclonal antibody that blocks angiogenesis) and/or poly–adenosine diphosphate ribose polymerase (PARP) inhibitors. With treatment, the 5-year overall survival rate for advanced-stage ovarian cancer is 10% to 40%. However, individuals with BRCA-related gene variants have a 5-year overall survival rate of approximately 70% with PARP inhibitor treatment. Despite an initial remission rate of 80%, approximately 75% of patients with advanced-stage disease have ovarian cancer relapse within 2 years. Conclusions and Relevance: Approximately 21 000 women are diagnosed with ovarian cancer annually in the US, and approximately 80% have advanced-stage ovarian cancer at diagnosis. First-line treatment of early-stage ovarian cancer is surgery and adjuvant platinum-based chemotherapy. Treatment of advanced-stage ovarian cancer includes cytoreductive surgery, platinum-based chemotherapy, and targeted maintenance therapies such as bevacizumab and/or PARP inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Ovarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21871 · Cited by 3,060
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,263
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,638
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
van Driel, W. J., Koole, S. N., Sikorska, K., Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H. M., de Hingh, I. H. J. T., van der Velden, J., Arts, H. J., Massuger, L. F. A. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708618 · Cited by 1,426
Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62223-6 · Cited by 1,414
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Bakitas, M. A., Tosteson, T. D., Li, Z., Lyons, K. D., Hull, J. G., Li, Z., Dionne-Odom, J. N., Frost, J., Dragnev, K. H., Hegel, M. T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.6362 · Cited by 1,216
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D.-Y., Banerjee, S., González-Martín, A., Jung, K. H., Ługowska, I., Manso, L., Manzano, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02005 · Cited by 1,069
Piccart, M. J. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.699 · Cited by 981
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Walsh, T., Casadei, S., Lee, M. K., Pennil, C. C., Nord, A. S., Thornton, A. M., Roeb, W., Agnew, K. J., Stray, S. M., Wickramanayake, A., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115052108 · Cited by 933
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 913
Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00086-8 · Cited by 875
Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 754
Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Trimbos, J. B., Vergote, I., Bolis, G., Vermorken, J. B., Mangioni, C., Madronal, C., Franchi, M., Tateo, S., Zanetta, G., Scarfone, G., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.113 · Cited by 674
Chi, D. S., Eisenhauer, E. L., Lang, J., Huh, J., Haddad, L., Abu-Rustum, N. R., Sonoda, Y., Levine, D. A., Hensley, M., & Barakat, R. R. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.03.051 · Cited by 634
Vasey, P. A., Jayson, G. C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J., Hay, A., Kaye, S. B., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh323 · Cited by 632
Vergote, I., De Brabanter, J., Fyles, A., Bertelsen, K., Einhorn, N., Sevelda, P., Gore, M. E., Kærn, J., Verrelst, H., Sjövall, K., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03590-x · Cited by 623
Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Harter, P., Sehouli, J., Lorusso, D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1808424 · Cited by 594
Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7519 · Cited by 575
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
DiSilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01549 · Cited by 511
Ovarian carcinoma diagnosis: Results of a national ovarian cancer survey
Goff, B. A., Mandel, L., Muntz, H. G., & Melancon, C. H. (2000) · Cancer · doi:10.1002/1097-0142(20001115)89:10<2068::aid-cncr6>3.0.co;2-z · Cited by 502
Frequency of Symptoms of Ovarian Cancer in Women Presenting to Primary Care Clinics
Goff, B. A. (2004) · JAMA · doi:10.1001/jama.291.22.2705 · Cited by 501
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
Moore, K. N., Angelergues, A., Konecny, G. E., García, Y., Banerjee, S., Lorusso, D., Lee, J.-Y., Moroney, J. W., Colombo, N., Roszak, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2309169 · Cited by 494
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Tewari, K. S., Burger, R. A., Enserro, D., Norquist, B. M., Swisher, E. M., Brady, M. F., Bookman, M. A., Fleming, G. F., Huang, H., Homesley, H. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01009 · Cited by 483
Miller, R. E., Leary, A., Scott, C. L., Serra, V., Lord, C. J., Bowtell, D., Chang, D. K., Garsed, D. W., Jonkers, J., Ledermann, J. A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2102 · Cited by 483
Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70363-2 · Cited by 480
Fagotti, A., Ferrandina, M. G., Vizzielli, G., Pasciuto, T., Fanfani, F., Gallotta, V., Margariti, P. A., Chiantera, V., Costantini, B., Gueli Alletti, S., et al. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001640 · Cited by 451
González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R. E., Pothuri, B., Ray-Coquard, I., Tan, D. S. P., Bellet, E., Oaknin, A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.011 · Cited by 449
Poveda, A., Floquet, A., Ledermann, J. A., Asher, R., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00073-5 · Cited by 422
Wright, A. A., Bohlke, K., Armstrong, D. K., Bookman, M. A., Cliby, W. A., Coleman, R. L., Dizon, D. S., Kash, J. J., Meyer, L. A., Moore, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.6907 · Cited by 409
Self-citationMonk, B. J., Parkinson, C., Lim, M. C., O'Malley, D. M., Oaknin, A., Wilson, M. K., Coleman, R. L., Lorusso, D., Bessette, P., Ghamande, S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01003 · Cited by 405
Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
Konstantinopoulos, P. A., Norquist, B., Lacchetti, C., Armstrong, D., Grisham, R. N., Goodfellow, P. J., Kohn, E. C., Levine, D. A., Liu, J. F., Lu, K. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02960 · Cited by 381
Tempany, C. M. C., Zou, K. H., Silverman, S. G., Brown, D. L., Kurtz, A. B., & McNeil, B. J. (2000) · Radiology · doi:10.1148/radiology.215.3.r00jn25761 · Cited by 381
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505067 · Cited by 367
Ray-Coquard, I., Leary, A., Pignata, S., Cropet, C., González-Martín, A., Marth, C., Nagao, S., Vergote, I., Colombo, N., Mäenpää, J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.005 · Cited by 365
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
Coleman, R. L., Spirtos, N. M., Enserro, D., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Kim, J.-W., Park, S.-Y., Kim, B.-G., Nam, J.-H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902626 · Cited by 338
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer
Harter, P., Sehouli, J., Vergote, I., Ferron, G., Reuss, A., Meier, W., Greggi, S., Mosgaard, B. J., Selle, F., Guyon, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103294 · Cited by 335
Aghajanian, C., Goff, B., Nycum, L. R., Wang, Y. V., Husain, A., & Blank, S. V. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.004 · Cited by 320
Daly, M. B., Pal, T., Maxwell, K. N., Churpek, J., Kohlmann, W., AlHilli, Z., Arun, B., Buys, S. S., Cheng, H., Domchek, S. M., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0051 · Cited by 315
Bell, J., Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., Rose, G. S., & Spirtos, N. M. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.06.013 · Cited by 307
Vergote, I., Coens, C., Nankivell, M., Kristensen, G. B., Parmar, M. K. B., Ehlen, T., Jayson, G. C., Johnson, N., Swart, A. M., Verheijen, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30566-7 · Cited by 306
Moore, K. N., Oza, A. M., Colombo, N., Oaknin, A., Scambia, G., Lorusso, D., Konecny, G. E., Banerjee, S., Murphy, C. G., Tanyi, J. L., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.017 · Cited by 305
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Helm, C. W., Richard, S. D., Pan, J., Bartlett, D., Goodman, M. D., Hoefer, R., Lentz, S. S., Levine, E. A., Loggie, B. W., Metzinger, D. S., et al. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181c50cde · Cited by 302
The disparate origins of ovarian cancers: pathogenesis and prevention strategies
Karnezis, A. N., Cho, K. R., Gilks, C. B., Pearce, C. L., & Huntsman, D. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.113 · Cited by 300
Cabasag, C. J., Fagan, P. J., Ferlay, J., Vignat, J., Laversanne, M., Liu, L., van der Aa, M. A., Bray, F., & Soerjomataram, I. (2022) · International Journal of Cancer · doi:10.1002/ijc.34002 · Cited by 292
ICON1 (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.125 · Cited by 287
Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2018) · JAMA · doi:10.1001/jama.2017.21926 · Cited by 283
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis
Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., Bernard, L., Maisonneuve, P., & Gandini, S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.018 · Cited by 281
Havrilesky, L. J., Moorman, P. G., Lowery, W. J., Gierisch, J. M., Coeytaux, R. R., Urrutia, R. P., Dinan, M., McBroom, A. J., Hasselblad, V., Sanders, G. D., et al. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318291c235 · Cited by 258
Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer
Walker, J. L., Powell, C. B., Chen, L., Carter, J., Bae Jump, V. L., Parker, L. P., Borowsky, M. E., & Gibb, R. K. (2015) · Cancer · doi:10.1002/cncr.29321 · Cited by 241
Shi, T., Zhu, J., Feng, Y., Tu, D., Zhang, Y., Zhang, P., Jia, H., Huang, X., Cai, Y., Yin, S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00006-1 · Cited by 239
Pignata, S., Scambia, G., Ferrandina, G., Savarese, A., Sorio, R., Breda, E., Gebbia, V., Musso, P., Frigerio, L., Del Medico, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8566 · Cited by 229
Lim, M. C., Chang, S.-J., Park, B., Yoo, H. J., Yoo, C. W., Nam, B. H., Park, S.-Y., Collaborators, H. F. O. C., Seo, S.-S., Kang, S., et al. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2022.0143 · Cited by 221
Satoh, T., Hatae, M., Watanabe, Y., Yaegashi, N., Ishiko, O., Kodama, S., Yamaguchi, S., Ochiai, K., Takano, M., Yokota, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8617 · Cited by 211
Rosenthal, A. N., Fraser, L. S. M., Philpott, S., Manchanda, R., Burnell, M., Badman, P., Hadwin, R., Rizzuto, I., Benjamin, E., Singh, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9330 · Cited by 209
Clamp, A. R., James, E. C., McNeish, I. A., Dean, A., Kim, J.-W., O'Donnell, D. M., Hook, J., Coyle, C., Blagden, S., Brenton, J. D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32259-7 · Cited by 209
Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer
Lawrie, T. A., Winter-Roach, B. A., Heus, P., & Kitchener, H. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004706.pub5 · Cited by 204
Marchetti, C., De Felice, F., Palaia, I., Perniola, G., Musella, A., Musio, D., Muzii, L., Tombolini, V., & Panici, P. B. (2014) · BMC Women's Health · doi:10.1186/s12905-014-0150-5 · Cited by 200
Wu, X. H., Zhu, J. Q., Yin, R. T., Yang, J. X., Liu, J. H., Wang, J., Wu, L. Y., Liu, Z. L., Gao, Y. N., Wang, D. B., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.018 · Cited by 200
Ferraro, S., Braga, F., Lanzoni, M., Boracchi, P., Biganzoli, E. M., & Panteghini, M. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201031 · Cited by 198
Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M. C., Fossati, R., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.307 · Cited by 189
Monk, B. J., Barretina-Ginesta, M. P., Pothuri, B., Vergote, I., Graybill, W., Mirza, M. R., McCormick, C. C., Lorusso, D., Moore, R. G., Freyer, G., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.08.2241 · Cited by 183
Surgical Staging and Treatment of Early Ovarian Cancer: Long-term Analysis From a Randomized Trial
Trimbos, B., Timmers, P., Pecorelli, S., Coens, C., Ven, K., van der Burg, M., & Casado, A. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq149 · Cited by 172
Yuan, Y., Gu, Z.-X., Tao, X.-F., & Liu, S.-Y. (2012) · European Journal of Radiology · doi:10.1016/j.ejrad.2011.01.112 · Cited by 166
Pfisterer, J., Shannon, C. M., Baumann, K., Rau, J., Harter, P., Joly, F., Sehouli, J., Canzler, U., Schmalfeldt, B., Dean, A. P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30142-x · Cited by 166
(2019) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003164 · Cited by 165
Endometriosis Typology and Ovarian Cancer Risk
Barnard, M. E., Farland, L. V., Yan, B., Wang, J., Trabert, B., Doherty, J. A., Meeks, H. D., Madsen, M., Guinto, E., Collin, L. J., et al. (2024) · JAMA · doi:10.1001/jama.2024.9210 · Cited by 164
Coleridge, S. L., Bryant, A., Kehoe, S. T., & Morrison, J. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005343.pub6 · Cited by 162
The systemic treatment of recurrent ovarian cancer revisited
Baert, T., Ferrero, A., Sehouli, J., O’Donnell, D. M., González-Martín, A., Joly, F., van der Velden, J., Blecharz, P., Tan, D. S. P., Querleu, D., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.015 · Cited by 161
Pignata, S., Lorusso, D., Joly, F., Gallo, C., Colombo, N., Sessa, C., Bamias, A., Salutari, V., Selle, F., Frezzini, S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30637-9 · Cited by 158
ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors
Timmerman, D., Planchamp, F., Bourne, T., Landolfo, C., du Bois, A., Chiva, L. M., Cibula, D., Concin, N., Fischerová, D., Froyman, W., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2021-002565 · Cited by 158
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline
Tung, N., Ricker, C. N., Messersmith, H. J., Balmañà, J., Domchek, S. M., Stoffel, E. M., Almhanna, K., Arun, B., Chávarri-Guerra, Y., Cohen, S. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00662 · Cited by 157
Hermsen, B. B. J., Olivier, R. I., Verheijen, R. H. M., van Beurden, M., de Hullu, J. A., Massuger, L. F. A. G., Burger, C. W., Brekelmans, C. T. M., Mourits, M. J. E., de Bock, G. H., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603725 · Cited by 155
Skates, S. J., Greene, M. H., Buys, S. S., Mai, P. L., Brown, P. H., Piedmonte, M., Rodriguez, G. C., Schorge, J. O., Sherman, M. E., Daly, M. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2750 · Cited by 154
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
Gaillard, S. L., Lacchetti, C., Armstrong, D. K., Cliby, W. A., Edelson, M. I., García, A. A., Ghebre, R. G., Gressel, G. M., Lesnock, J. L., Meyer, L. A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02589 · Cited by 143
Self-citationMichielsen, K., Dresen, R. C., Vanslembrouck, R. A., Keyzer, F. D., Amant, F. C., Mussen, E., Leunen, K., Berteloot, P., Moerman, P., Vergote, I. B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.010 · Cited by 139
Hoerger, M. P., Wayser, G. R., Schwing, G., Suzuki, A., & Perry, L. M. (2018) · Annals of Behavioral Medicine · doi:10.1093/abm/kay077 · Cited by 139
Antonio, C. C. P., Alida, G. G., Elena, G. G., Rocío, G. S., Jerónimo, M. G., Alonso-Romero, J. L., Díaz, A. N., Valcárcel, F. B., Jesús, G. R. Á., Ramírez-Romero, P., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11087-7 · Cited by 127
Accuracy of CA 125 in the diagnosis of ovarian tumors: A quantitative systematic review
Medeiros, L. R., Rosa, D. D., da Rosa, M. I., & Bozzetti, M. C. (2008) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2008.08.011 · Cited by 126
ACR Appropriateness Criteria ® Staging and Follow-Up of Ovarian Cancer
Kang, S. K., Reinhold, C., Atri, M., Benson, C. B., Bhosale, P., Jhingran, A., Lakhman, Y., Maturen, K. E., Nicola, R., Pandharipande, P. V., et al. (2018) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2018.03.015 · Cited by 116
Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation
Kotsopoulos, J., Gronwald, J., Karlan, B., Rosen, B., Huzarski, T., Moller, P., Lynch, H. T., Singer, C. F., Senter, L., Neuhausen, S. L., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.05.011 · Cited by 109
Tanha, K., Mottaghi, A., Nojomi, M., Moradi, M., Rajabzadeh, R., Lotfi, S., & Janani, L. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00911-z · Cited by 97
Optimal treatment of early-stage ovarian cancer
Collinson, F. J., Qian, W., Fossati, R., Lissoni, A. A., Williams, C., Parmar, M., Ledermann, J. A., Colombo, N., & Swart, A. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu116 · Cited by 89
Caruso, G., Tomao, F., Parma, G., Lapresa, M., Multinu, F., Palaia, I., Aletti, G. D., & Colombo, N. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-004149 · Cited by 56
Self-citationFischerová, D., Pinto, P., Burgetová, A., et al. (2021) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.23654 · Cited by 51
Clamp, A. R., James, E. C., McNeish, I. A., Dean, A. P., Kim, J.-W., O’Donnell, D. M., Gallardo‐Rincón, D., Blagden, S. P., Brenton, J. D., Perren, T. J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00283-2 · Cited by 47
Liu, S., Kasherman, L., Fazelzad, R., Wang, L. E., Bouchard‐Fortier, G., Lheureux, S., & Krzyzanowska, M. K. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.01.028 · Cited by 44
van Bommel, M. H. D., IntHout, J., Veldmate, G., Kets, C. M., de Hullu, J. A., van Altena, A. M., & Harmsen, M. G. (2022) · Human Reproduction Update · doi:10.1093/humupd/dmac038 · Cited by 43
Jiang, R., Feng, Y., Chen, Y., Cheng, X., Shi, T., Gao, W., Jia, H., Jiang, S., Guo, Y., Huang, X., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02981-0 · Cited by 41
Wu, X., Zhu, J., Yin, R., Yang, J., Liu, J., Wang, J., Wu, L., Liu, Z., Gao, Y., Wang, D., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102629 · Cited by 28
FIGO position statement on opportunistic salpingectomy as an ovarian cancer prevention strategy
Mor‐Hadar, D., Wilailak, S., Berek, J. S., & McNally, O. (2024) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.15884 · Cited by 27
Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer
Lai, T. S., Kessel, B., Ahn, H. J., & Terada, K. Y. (2016) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2016.27.e41 · Cited by 16
Metadata
- Authors
- Caruso, G., Weroha, S. J., & Cliby, W.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2025-10-14
- Volume
- 334
- Issue
- 14
- Pages
- 1278
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4412528048
- Cited by
- 304
- References
- 116
- FWCI
- 208.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.